Barry L. Templin, Executive Vice President and Chief Technology Officer of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on August 14, 2026, disclosing the acquisition of 26,246 restricted stock units and a stock option covering 36,312 shares of common stock, both granted on August 13, 2026.

Key Highlights

  • RSU Grant: Barry L. Templin acquired 26,246 restricted stock units at a price of $0, representing a contingent right to receive one share of common stock each.
  • Stock Option Grant: Templin also acquired a stock option to purchase 36,312 shares of common stock at an exercise price of $21.95, expiring August 12, 2036.
  • RSU Vesting Schedule: One-quarter of the RSUs vest on August 13, 2027, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months, subject to continued service.
  • Option Vesting Schedule: The stock option vests at 1/48th of the shares monthly beginning August 13, 2026, over a four-year period, subject to continued employment or service.
  • Advance Grant Structure: According to the filing, both grants are intended to represent 50% of the value of the reporting person's expected 2027 grant, and are made in lieu of that portion of the expected 2027 grant.
  • Post-Transaction Ownership: Following the reported transactions, Templin directly and beneficially owns 95,199 shares of common stock and 36,312 derivative securities.

PROCEPT BioRobotics CTO Templin Receives Equity Awards Ahead of 2027 Cycle

According to the Form 4 filed with the SEC on August 14, 2026, Barry L. Templin, serving as EVP and Chief Technology Officer of PROCEPT BioRobotics Corp, received two separate equity awards on August 13, 2026. The first is a grant of 26,246 restricted stock units (RSUs), each representing a contingent right to receive one share of the company's common stock. The second is a stock option granting the right to purchase 36,312 shares of common stock at an exercise price of $21.95 per share, with an expiration date of August 12, 2036. Both transactions were coded as acquisitions (Code A) at a price of $0 to the reporting person.

The filing's footnotes explain the structure of each award. The RSUs are scheduled to begin vesting with one-quarter of the total on August 13, 2027, followed by one-sixteenth of the remaining units vesting quarterly over the subsequent 36 months, in each case conditioned on Templin continuing as a service provider through the applicable vesting date. The stock option vests at 1/48th of the total shares per month from the vesting commencement date of August 13, 2026, over a four-year period, subject to continued employment or service.

The filing notes that both grants "are intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant." Following these transactions, Templin's direct beneficial ownership stands at 95,199 shares of common stock and 36,312 derivative securities. The Form 4 was signed by Jonathan Stone as attorney-in-fact for Barry Templin and filed on August 14, 2026.

What Was Disclosed

The filing discloses two equity awards granted to PROCEPT BioRobotics Corp's CTO on August 13, 2026: 26,246 RSUs and a stock option covering 36,312 shares at $21.95, each described as representing 50% of the reporting person's expected 2027 grant.